Novo Nordisk — trend history

▲ Peaking Business

Novo Nordisk shares decline despite Q2 profit beats and raised forecasts, amid intensifying competition with Eli Lilly.

9 sources 10 articles v 38 1h ago

◼ Archived Business 🔮 fades ✓

Pharmaceutical giant Novo Nordisk faces a significant setback following the failure of a late-stage cardiovascular drug trial.

1 sources 1 articles v 0 3d ago

◼ Archived Business 🔮 fades ✓

Novo Nordisk faces a significant setback in expanding beyond obesity as a key phase 3 trial delivers disappointing results.

1 sources 1 articles v 0 3d ago

◼ Archived Business 🔮 holds

Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of deceptive and misleading advertising regarding GLP-1 weight-loss drugs.

11 sources 11 articles v 9 13d ago

◼ Archived Business 🔮 fades

Novo Nordisk has launched a legal offensive against Eli Lilly, alleging that the competitor's GLP-1 weight-loss drug advertising is deceptive.

7 sources 7 articles v 5 14d ago

◼ Archived Health 🔮 fades

FDA’s new peptide panel sparks regulatory debate as biotech giants Lilly and Novo eye the next health wave.

5 sources 5 articles v 3 18d ago

◼ Archived Business 🔮 fades

Novo Nordisk and Vivani are partnering to develop a long-acting semaglutide implant designed to improve weight loss adherence for up to a year.

5 sources 5 articles v 3 24d ago

◼ Archived Business 🔮 fades

Medicare has introduced $50 prescriptions for GLP-1 medications, signaling a potential shift in the US healthcare and pharmaceutical landscape.

3 sources 3 articles v 1 32d ago

◼ Archived Business 🔮 holds

13 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

13 sources 15 articles v 14 47d ago